SpyGlass shares 4-year IOP reduction data for BIM-IOL system post-cataract surgery
SpyGlass Pharma announced positive 4-year safety and efficacy results from a first-in-human trial of its BIM-IOL System, showing significant intraocular pressure reduction and drop independence while maintaining visual acuity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed